Tags : Neovascular Macular Degeneration

Allergan and Molecular Partners Report Result of Abicipar pegol in

Shots: The P-III MAPLE study involves assessing of abicipar pegol (2mg, q8w) in 123 patients with Neovascular Macular Degeneration (nAMD) for 28 wks. P-III MAPLE study results: 8.9% incidence of intraocular inflammation (IOI)lower than P-III studies (CEDAR and SEQUOIA); severe IOI 1.6%; no reported cases of endophthalmitis or retinal vasculitis in this study Abicipar is […]Read More